RARE
Ultragenyx Pharmaceutical Inc.
40.51
USD
This page is just a preview of the data found in TrendSpider’s full version
Ultragenyx Pharmaceutical Inc. stock is up 16.11% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 December’s closed higher than November. In the last 8 Unusual Options Trades, there were 6 CALLs, 2 PUTs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 16 Oct 18:52 | 17 Nov, 2023 | 40.00 | 919 | ||
| 18 Oct 18:22 | 20 Oct, 2023 | 40.00 | 133 | ||
| 20 Oct 14:42 | 19 Jan, 2024 | 30.00 | 9 | ||
| 17 Nov 18:12 | 16 Feb, 2024 | 45.00 | 1 | ||
| 01 Dec 17:42 | 19 Jan, 2024 | 40.00 | 244 | ||
| 01 Dec 17:44 | 19 Jan, 2024 | 40.00 | 244 | ||
| 01 Dec 20:20 | 19 Jan, 2024 | 35.00 | 316 | ||
| 01 Dec 20:28 | 19 Jan, 2024 | 35.00 | 316 |
Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the. treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.
